Moderna raised $2.6 billion via an upsized offering, tying the financing to momentum in its cancer work. The capital raise followed a major win in a key study, positioning Moderna to accelerate manufacturing and pipeline execution while navigating heightened scrutiny on trial disclosures and timing. The move reflects continued investor demand for scale-up capacity in oncology and immunology programs, even as the company faces near-term communications and execution risks typical of late-stage development. For the sector, the size of the raise signals that public markets are still funding platform-scale bets—particularly when paired with credible clinical signals.